BNP Paribas Financial Markets Cuts Stock Position in Evolus, Inc. (NASDAQ:EOLS)

BNP Paribas Financial Markets cut its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 42.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,213 shares of the company's stock after selling 26,535 shares during the quarter. BNP Paribas Financial Markets owned about 0.06% of Evolus worth $400,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in EOLS. KBC Group NV bought a new stake in shares of Evolus in the fourth quarter valued at $49,000. IFP Advisors Inc raised its stake in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the fourth quarter valued at $106,000. Quantbot Technologies LP bought a new stake in shares of Evolus in the fourth quarter valued at $118,000. Finally, Freestone Grove Partners LP bought a new stake in shares of Evolus during the 4th quarter valued at $140,000. 90.69% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. This represents a 1.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rui Avelar sold 3,385 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the transaction, the insider now owns 359,082 shares of the company's stock, valued at $3,544,139.34. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock worth $1,048,666 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Evolus Price Performance

NASDAQ EOLS traded down $0.51 during trading on Wednesday, reaching $9.30. The company's stock had a trading volume of 2,382,319 shares, compared to its average volume of 700,527. The stock has a market capitalization of $599.63 million, a PE ratio of -10.22 and a beta of 1.11. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a fifty day moving average of $10.82 and a 200 day moving average of $12.04. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EOLS shares. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.